Expression of the serotonin 1b receptor in experimental pulmonary hypertension

被引:30
作者
Rondelet, B
Van Beneden, R
Kerbaul, F
Motte, S
Fesler, P
McEntee, K
Brimioulle, S
Ketelslegers, JM
Naeije, R
机构
[1] Free Univ Brussels, Physiol Lab, B-1070 Brussels, Belgium
[2] Catholic Univ Louvain, Univ Diabet & Nutr, B-3000 Louvain, Belgium
[3] Erasme Univ Hosp, Dept Intens Care, B-1070 Brussels, Belgium
[4] Timone Hosp, Unite Reaminat Chirurg Cardiaque, Marseille, France
关键词
endothelin experimental; pulmonary arterial hypertension; pulmonary vascular impedance; serotonin; systemic-to-pulmonary shunting;
D O I
10.1183/09031936.03.00036203
中图分类号
R56 [呼吸系及胸部疾病];
学科分类号
摘要
The pathogenesis of pulmonary arterial hypertension (PAH) remains uncertain. Both the serotonin and endothelin (ET) systems are believed to be involved. Recent studies pointed to the importance of the serotonin 2B receptor as a limiting step. The current authors investigated the lung tissue expression of serotonin receptors and of the serotonin transporter (5-HTT) by real-time-quantitative polymerase chain reaction in chronic overcirculation-induced PAH in growing piglets, with and without treatment with the dual ET receptor blocker bosentan. Pulmonary haemodynamic changes were described by pulmonary arterial impedance spectra. Three months after the surgical anastomosis of the left subclavian artery to the pulmonary arterial trunk, there was a shift of the impedance spectra to higher ratios of pressure and flow moduli, with increases in both 0 Hz impedance and characteristic impedance, and these changes were completely prevented by bosentan therapy. There was an increase in the expression of the serotonin 1B receptor. There was no change in the expression of the 5-HTT, and of the serotonin 2B, 1D, and 4 receptors. The overexpression of the serotonin 1B receptor was partially prevented by bosentan therapy. The present authors conclude that this early pulmonary arterial hypertension model is characterised by an endothelin receptor-dependent increased expression of the serotonin 1B receptor.
引用
收藏
页码:408 / 412
页数:5
相关论文
共 24 条
[1]   Appetite-suppressant drugs and the risk of primary pulmonary hypertension [J].
Abenhaim, L ;
Moride, Y ;
Brenot, F ;
Rich, S ;
Benichou, J ;
Kurz, X ;
Higenbottam, T ;
Oakley, C ;
Wouters, E ;
Aubier, M ;
Simonneau, G ;
Begaud, B .
NEW ENGLAND JOURNAL OF MEDICINE, 1996, 335 (09) :609-616
[2]   EFFECTS OF A CHRONIC AORTOPULMONARY SHUNT ON PULMONARY HEMODYNAMICS IN PIGLETS [J].
DECANNIERE, D ;
STEFANIDIS, C ;
BRIMIOULLE, S ;
NAEIJE, R .
JOURNAL OF APPLIED PHYSIOLOGY, 1994, 77 (04) :1591-1596
[3]   Pathobiology of pulmonary arterial hypertension [J].
Eddahibi, S ;
Morrell, N ;
D'Ortho, MP ;
Naeije, R ;
Adnot, S .
EUROPEAN RESPIRATORY JOURNAL, 2002, 20 (06) :1559-1572
[4]   PROTECTION FROM PULMONARY-HYPERTENSION WITH AN ORALLY-ACTIVE ENDOTHELIN RECEPTOR ANTAGONIST IN HYPOXIC RATS [J].
EDDAHIBI, S ;
RAFFESTIN, B ;
CLOZEL, M ;
LEVAME, M ;
ADNOT, S .
AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY, 1995, 268 (02) :H828-H835
[5]   Serotonin transporter overexpression is responsible for pulmonary artery smooth muscle hyperplasia in primary pulmonary hypertension [J].
Eddahibi, S ;
Humbert, M ;
Fadel, E ;
Raffestin, B ;
Darmon, M ;
Capron, F ;
Simonneau, G ;
Dartevelle, P ;
Hamon, M ;
Adnot, S .
JOURNAL OF CLINICAL INVESTIGATION, 2001, 108 (08) :1141-1150
[6]   Clinical classification of pulmonary hypertension [J].
Fishman, AP .
CLINICS IN CHEST MEDICINE, 2001, 22 (03) :385-+
[7]  
Grant BJB, 1997, EUR RESPIR J, V10, P1933
[9]   INCREASED PLASMA SEROTONIN IN PRIMARY PULMONARY-HYPERTENSION [J].
HERVE, P ;
LAUNAY, JM ;
SCROBOHACI, ML ;
BRENOT, F ;
SIMONNEAU, G ;
PETITPRETZ, P ;
POUBEAU, P ;
CERRINA, J ;
DUROUX, P ;
DROUET, L .
AMERICAN JOURNAL OF MEDICINE, 1995, 99 (03) :249-254
[10]   PULMONARY VASCULAR-DISEASE WITH CONGENITAL HEART LESIONS - PATHOLOGIC FEATURES AND CAUSES [J].
HOFFMAN, JIE ;
RUDOLPH, AM ;
HEYMANN, MA .
CIRCULATION, 1981, 64 (05) :873-877